OT mobile menu

Search form


Hematologic Cancer Targets

Is Cytomegalovirus Linked to Childhood Leukemia Risk?

These findings suggest the possibility that ALL could be prevented with antiviral interventions or vaccination. Image © Jarun Ontakrai/Shutterstock.com 

Hematologic Cancer Targets

The phase III ALCYONE study showed that daratumumab in combination with bortezomib, melphalan, and prednisone is a viable front-line option for myeloma patients who are not candidates for ASCT.

Researchers at St. Jude Children’s Research Hospital have discovered a vulnerability that may easily translate into new targeted drug therapies that block heme biosynthesis, killing leukemic cells.

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

A new study indicates that patients with primary immunodeficiency diseases may be at a much higher risk for certain cancers, especially lymphoma.

In this interview with Charlotte Pawlyn, MB, BChir, PhD, she discusses results of the Myeloma XI study, which tested a novel quadruplet therapy for patients with newly diagnosed multiple myeloma.

A large genomic sequencing analysis of patients with T-ALL revealed a new landscape of mutations that may inform future treatment strategies.

A follow-up analysis of the CheckMate-205 clinical trial found that nivolumab was associated with durable response rates in adults with relapsed or refractory Hodgkin lymphoma after ASCT.


Subscribe to Hematologic Cancer Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.